October 2020

Manuscript

OncoImmunology

May 2020

Abstract

AACR Annual Meeting

May 2020

Abstract

ASCO Annual Meeting

Uptake of first-line immune checkpoint inhibitors among medically frail patients with advanced solid malignancies

Parikh, RB, Cohen, RB, Min, EJ, Wileyto, EP, Riaz, F, Gross, CP, Long, Q, Mamtani, R

May 2020

Abstract

ASCO Annual Meeting

February 2020

Abstract

ASCO GU Symposium

Flatiron-authored

First-line immune checkpoint inhibitor use in cisplatin-eligible patients with advanced urothelial carcinoma: a secular trend analysis

Parikh, RB, Feld, EK, Galsky, MD, Adamson, BJS, Cohen, AB, Baxi, SS, Boursi, SB, Christodouleas, JP, Vaughn, DJ, Meropol, NJ, Mamtani, R

December 2019

Manuscript

Future Oncology

Flatiron-authored

Association of baseline systemic corticosteroid use with time to next treatment in patients with advanced melanoma, non-small cell lung cancer or urothelial cancer receiving cancer immunotherapy in US clinical practice

Drakaki, A, Dhillon, PK, Wakelee, H, Chui, S, Shim, J, Kent, M, Degaonkar, V, Hoang, T, McNally, V, Luhn, P, Gutzmer, R

December 2019

Abstract

ESMO Immuno-Oncology Congress

Association between FDA label restriction and immunotherapy and chemotherapy use in bladder cancer

Parikh RB, Adamson BJS, Khozin S, Galsky MD, Baxi SS, Cohen A, Mamtani R

September 2019

Manuscript

JAMA

Flatiron-authored

Effectiveness of first-line immune checkpoint blockade versus carboplatin-based chemotherapy for metastatic urothelial cancer

Feld E, Harton J, Meropol NJ, Adamson BJS, Cohen A, Parikh RB, Galsky MD, Narayan V, Christodouleas J, Vaughn DJ, Hubbard RA, Mamtani R

July 2019

Manuscript

European Urology

Flatiron-authored

Affordable Care Act Medicaid expansion impact on racial disparities in time to cancer treatment

Adamson B, Cohen AB, Estevez M, Magee K, Williams E, Gross CP, Meropol NJ, Davidoff AJ

June 2019

Abstract

ASCO Annual Meeting

Flatiron-authored

June 2019

Abstract

ASCO Annual Meeting

June 2019

Abstract

ASCO Annual Meeting

Carboplatin-based chemotherapy versus immunotherapy in metastatic urothelial carcinoma

Feld E, Harton J, Meropol NJ, Adamson B, Parikh RB, Galsky MD, Cohen AB, Narayan V, Christodouleas JP, Vaughn DJ, Hubbard RA, Mamtani R

June 2019

Abstract

ASCO Annual Meeting

Flatiron-authored

April 2019

Manuscript

Cancer Epidemiology

Trends in Checkpoint Inhibitor Therapy for Advanced Urothelial Cell Carcinoma at the End of Life: Insights from Real-World Practice

Parikh RB, Galsky MD, Gyawali B, Riaz F, Kaufmann T, Cohen AB, Adamson BJS, Gross CP, Meropol NJ, Mamtani R.

April 2019

Manuscript

The Oncologist

Flatiron-authored

Real-world trends in first-line checkpoint inhibitor use in advanced urothelial cell carcinoma

Parikh RB, Galsky MD, Baxi SS, Adamson B, Cohen AB, Feld E, Christodouleas JP, Boursi SB, Meropol NJ, Mamtani R

February 2019

Abstract

ASCO GU Symposium

Trends in checkpoint inhibitor therapy for advanced urothelial cell carcinoma at the end of life: Insights from real-world practice

Parikh RB, Galsky MD, Gyawali B, Riaz F, Kaufmann TL, Cohen AB, Adamson B, Gross CP, Meropol NJ, Mamtani R

February 2019

Abstract

ASCO GU Symposium

February 2019

Abstract

ASCO GU Symposium

February 2019

Abstract

ASCO GU Symposium

October 2018

Abstract

ESMO Annual Congress